Merck has wrapped up its previously announced $1.85 billion acquisition of Massachusetts-based clinical-stage biotech company Pandion Therapeutics. The pharma giant said that it had successfully completed the cash tender offer, via a subsidiary, for all of the outstanding shares of Pandion Therapeutics at $60 per share. After the finalization of the tender offer, Merck closed […]
Merck has agreed to acquire Pandion Therapeutics, a Massachusetts-based clinical-stage biotech company, for about $1.85 billion in an all-cash deal. Pandion Therapeutics is engaged in developing therapeutics for addressing the unmet needs of patients suffering from autoimmune diseases. The US biotech company is being acquired by Merck for $60 per share. Commenting on Merck acquisition […]
Day One Biopharmaceuticals has signed a licensing agreement with Merck to develop and commercialize pimasertib and MSC2015103B, two oral, small molecule allosteric inhibitors of MEK 1/2. MEK 1/2 is a key enzyme in the MAPK signaling pathway whose dysregulation has been shown to occur in various cancers. Pimasertib has been evaluated in over 10 phase […]
V114 pneumococcal conjugate vaccine candidate : Merck has submitted applications to the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) seeking approval for V114, its 15-valent pneumococcal conjugate vaccine candidate. The Merck vaccine candidate is intended for use in adults 18 years of age and older. The pharma giant said that it […]
Merck acquisition of OncoImmune : Pharma giant Merck has signed an all-cash deal worth $425 million to acquire OncoImmune to gain access to the latter’s investigational Covid-19 drug – CD24Fc. Based in Maryland, OncoImmune is a clinical-stage biopharma company, that is focused on the discovery and development of therapies for cancer and autoimmune disease. As […]
Merck acquisition of VelosBio : US pharma giant Merck has agreed to acquire VelosBio, a California-based clinical-stage biopharma company, for $2.75 billion in an all-cash deal, in a move to strengthen its oncology pipeline. VelosBio is engaged in developing cancer therapies that target receptor tyrosine kinase-like orphan receptor 1 (ROR1). The company’s lead investigational candidate […]
US biotech company Seattle Genetics has secured deals worth up to $4.4 billion with Merck, that include two new strategic oncology collaborations. The two major pharma companies will develop and commercialize Seattle Genetics’ ladiratuzumab vedotin across the world. Ladiratuzumab vedotin is an investigational antibody-drug conjugate (ADC) that targets LIV-1, which is presently in phase 2 […]
Massachusetts-based Yumanity Therapeutics has secured a drug development deal worth up to nearly $500 million with pharma giant Merck to develop new therapies for neurodegenerative disorders. The partnership is set to combine the drug discovery platform of Yumanity Therapeutics with the development and commercialization expertise in neuroscience of Merck. As per the deal, Merck will […]
Pharma giant Merck has wrapped up its previously announced acquisition of Austrian vaccine developer Themis Bioscience. The Austrian company is focused on developing vaccines and immune-modulation therapies for infectious diseases and cancer. Merck announced the deal last month in a move to gain access to Themis Bioscience’s coronavirus vaccine candidate. Read more about Merck acquisition […]
Merck acquisition of Themis Bioscience : Merck has signed a deal to acquire Themis Bioscience, an Austrian vaccine developer for an undisclosed price with an objective to gain access to the latter’s coronavirus vaccine candidate. Themis Bioscience by leveraging its measles virus vector platform has developed a pipeline of vaccine candidates and immune-modulatory therapies. Recently, […]